| Name | NP10679 |
| Description | NP10679 is an orally available, selective, brain-penetrating, potent, and pH-sensitive N-methyl-D-aspartate (NMDA) receptor inhibitor of the GluN2B subunit.NP10679 inhibits histamine H1, hERG channels, and CYP enzymes, and may be useful in the study of epilepsy and ischemic stroke. |
| In vitro | NP10679 is an NMDA receptor inhibitor containing GluN2B that is more effective than physiological pH. It exhibits inhibitory effects on 5-HT2A, α1A adrenergic receptor, H1 histamine receptor, and hERG channels[2]. |
| In vivo | In the Male C57BL/6 middle cerebral artery occlusion (MCAo) model of transient ischemia mice, NP10679 (2, 5, and 10 mg/kg; intraperitoneal injection; administered 15 minutes prior to transient ischemia) dose-dependently reduces infarct volumes, with an ED50 of 1 mg/kg[2]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 80 mg/mL (177.99 mM), Sonication is recommended.
|
| Keywords | NMDA receptor | HistamineReceptor | Histamine Receptor | hERG | CYP |
| Inhibitors Related | Undecane | Oxadiazon | Meclizine dihydrochloride | Urethane | Ipriflavone | Famotidine | Benzyl alcohol | 1,8-Cineole | Sodium butanoate | Naringin | Alginic acid | Dibenzothiophene |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |